DC Element | Wert | Sprache |
dc.contributor.author | Liyanage, A. | |
dc.contributor.author | Liyanage, G. | |
dc.contributor.author | Sirimanna, G. | |
dc.contributor.author | Schürer, N. | |
dc.date.accessioned | 2023-02-17T12:15:11Z | - |
dc.date.available | 2023-02-17T12:15:11Z | - |
dc.date.issued | 2022 | |
dc.identifier.issn | 1941-2789 | |
dc.identifier.uri | http://osnascholar.ub.uni-osnabrueck.de/handle/unios/65865 | - |
dc.description.abstract | OBJECTIVE: Skin lightening agents are popular in southern Asia, but there is dearth of evidence on their effectiveness on Fitzpatrick IV/V skin types. This study was designed to assess the depigmenting efficacy of commercially available and specifically formulated ointments using the Mexameter® (MX 18). METHODS: This single center prospective study was performed to test five commercially available preparations (Eldopaque®, Aziderm®, Garnier Dark Spot Corrector®, Ban a Tan Cream® and Neostrata Pigment Lightening Gel) on 28 healthy female volunteers in Phase 1, while five single active ingredients in lipophilic dispersion (hydroquinone 4%, ascorbyl palmitate 1%, resveratrol 1% arbutin 5% and azelaic acid 20%) were tested on a different group of 26 healthy female volunteers in Phase 2. The test agents were applied twice a day for five days per week and continued for six weeks in both study phases. Weekly Mexameter® measurements were obtained from test sites and negative controls. RESULTS: Significant hypopigmentation when compared to untreated controls was observed with Aziderm cream (p<0.05, MWU) and the Neostrata Pigment Lightening Gel (p<0.05, MWU). All formulated preparations showed significant reduction in pigmentation; however, only the arbutin (5%) containing formulation revealed significant attenuation of pigmentation in comparison to the inactive control (p<0.05, MWU). CONCLUSION: All applications containing active ingredients showed significant skin lightening; however, only arbutin was able to demonstrate significant diminution of pigmentation when compared to the inactive control. © 2022 Matrix Medical Communications. All rights reserved. | |
dc.language.iso | en | |
dc.publisher | Matrix Medical Communications | |
dc.relation.ispartof | Journal of Clinical and Aesthetic Dermatology | |
dc.subject | arbutin, 497-76-7 | |
dc.subject | ascorbyl palmitate, 137-66-6 | |
dc.subject | azelaic acid, 123-99-9 | |
dc.subject | hydroquinone, 123-31-9 | |
dc.subject | resveratrol, 501-36-0 | |
dc.subject | arbutin | |
dc.subject | Article | |
dc.subject | ascorbyl palmitate | |
dc.subject | azelaic acid | |
dc.subject | aziderm | |
dc.subject | ban a tan | |
dc.subject | comparative study | |
dc.subject | controlled study | |
dc.subject | cream | |
dc.subject | dark spot corrector | |
dc.subject | data analysis software | |
dc.subject | dispersion | |
dc.subject | drug efficacy | |
dc.subject | drug formulation | |
dc.subject | drug safety | |
dc.subject | female | |
dc.subject | Fitzpatrick IV/V skin type | |
dc.subject | human | |
dc.subject | hydroquinone | |
dc.subject | hypopigmentation | |
dc.subject | lipophilicity | |
dc.subject | Mexameter® | |
dc.subject | neostrata pigment lightening gel | |
dc.subject | normal human | |
dc.subject | ointment | |
dc.subject | prospective study | |
dc.subject | resveratrol, adult | |
dc.subject | skin color | |
dc.subject | Skin lightening preparations | |
dc.title | Comparative Study on Depigmenting Agents in Skin of Color | |
dc.type | journal article | |
dc.identifier.scopus | 2-s2.0-85132902922 | |
dc.identifier.url | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85132902922&partnerID=40&md5=8e2e7826c7e2bfbbb322125bae6f2b91 | |
dc.description.volume | 15 | |
dc.description.issue | 2 | |
dc.description.startpage | 12 | |
dc.description.endpage | 17 | |
dcterms.isPartOf.abbreviation | J. Clin. Aesthetic Dermatol. | |
crisitem.author.dept | FB 08 - Humanwissenschaften | - |
crisitem.author.deptid | fb08 | - |
crisitem.author.parentorg | Universität Osnabrück | - |
crisitem.author.netid | ScNa997 | - |